Deprecated!
This application is deprecated. Please use the latest version of the tool here.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
DIANA-TarBase v7 is available for scientific non-profit and non-commercial use! Download TarBase v7 by following this link
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all 
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Loading... |
| Wait until the result set is completed... |
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:87399016-87399038 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:100034959-100034982 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:100034959-100034982 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:127371084-127371098 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:127371084-127371098 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:149591501-149591522 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:29261650-29261676 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:29261650-29261676 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:52594268-52594290 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:48423047-48423075 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:58490537-58490561 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:58490537-58490561 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:58490537-58490561 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:122061740-122061763 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:115412164-115412173 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:17343926-17343948 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:17344372-17344396 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:171555676-171555702 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:39032773-39032793 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:132374647-132374671 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:1130050-1130075 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr10:1130050-1130075 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:67305266-67305288 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:105100766-105100791 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:224473682-224473705 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:38700591-38700616 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:41307571-41307597 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:60445962-60445985 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:60445962-60445985 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
qPCR
POSITIVE
INDIRECT
Tarbase 7.0
UNKNOWN
Western Blot
POSITIVE
INDIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:69652271-69652318 (UNKNOWN)
CTGACTAGTTCCTACGATACGCTACTATAAAGAG
TTGGAGCTCAAGTGCTTGGAAATGGAATG
Luciferase Reporter Assay
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
qPCR
POSITIVE
INDIRECT
Tarbase 7.0
UNKNOWN
Western Blot
POSITIVE
INDIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:69652271-69652318 (UNKNOWN)
CTGACTAGTTCCTACGATACGCTACTATAAAGAG
TTGGAGCTCAAGTGCTTGGAAATGGAATG
Luciferase Reporter Assay
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:69652277-69652301 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:56932557-56932583 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:96576680-96576706 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:112033274-112033298 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:114496412-114496439 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:57215338-57215363 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr19:57215473-57215498 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:84517672-84517693 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:26413873-26413899 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:26413873-26413899 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:92609982-92610010 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:32979434-32979458 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:32979434-32979458 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:47571949-47571977 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:14208500-14208523 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:42300975-42300996 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:144380600-144380623 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:42085103-42085125 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:133589343-133589369 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:133589343-133589369 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:74873701-74873725 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:61943553-61943576 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:5742393-5742416 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr10:5763523-5763544 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr10:5763523-5763544 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr10:5763523-5763544 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:128148836-128148862 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:135927316-135927339 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:135927316-135927339 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:135928247-135928270 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:103595717-103595737 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:24781493-24781521 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:55394284-55394311 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:132880266-132880286 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:132934713-132934738 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:60294979-60295006 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:27979701-27979723 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:100281597-100281619 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr15:52065527-52065553 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:58160955-58160982 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ARMC6 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:19059807-19059830 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DDX6 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:118749506-118749531 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TARS (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:33458626-33458650 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:33458626-33458650 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:33458626-33458650 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
N4BP2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:40156234-40156256 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RNH1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:494523-494547 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:494523-494547 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:494523-494547 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:494523-494547 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RABEP1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:5383919-5383942 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TOLLIP (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:1275054-1275076 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ADD1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:2929333-2929358 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RNF31 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:24155190-24155215 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GTPBP10 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:90388939-90388964 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:90385028-90385052 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CECR2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:17555578-17555600 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DDHD1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:53046627-53046646 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:53044748-53044769 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NUP88 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:5416604-5416626 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:5416604-5416626 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SLC25A3 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:98597883-98597907 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:98597883-98597907 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DICER1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:95103392-95103415 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
UNKL (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:1363274-1363296 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr16:1365855-1365881 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RPGRIP1L (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:53694127-53694148 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
REV3L (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:111376487-111376515 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CECR1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:17180720-17180743 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TNRC6B (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:40312972-40312994 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr22:40312972-40312994 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr22:40335342-40335365 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DGKH (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:42229875-42229897 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PIAS1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr15:68086554-68086577 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KMT2E (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:105112502-105112526 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:105112502-105112526 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:105102131-105102159 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NCKAP1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:182981339-182981361 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RAB5C (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:42125704-42125727 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:42125704-42125727 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MKNK2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:2037588-2037604 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:2037588-2037604 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:2037588-2037604 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:2037588-2037604 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:2037588-2037604 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
BAIAP2L1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:98315463-98315487 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TNRC6A (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:24818676-24818697 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ARID4B (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:235168382-235168403 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:235167395-235167419 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DCPS (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:126345416-126345438 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
JAG1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr20:10638599-10638623 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MCUR1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:13786843-13786866 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:13788441-13788462 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZC3H14 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:88572732-88572756 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZC3HAV1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:139079898-139079922 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KDM5A (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:282811-282834 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KLHL42 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:27799937-27799965 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GLTSCR1L (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:42866844-42866867 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MPP5 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:67334789-67334813 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67334789-67334813 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67334461-67334484 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr14:67334789-67334813 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
VDR (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:47841582-47841604 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GID8 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr20:62946208-62946236 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PSME4 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:53920960-53920983 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZFYVE26 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:67746772-67746793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MKRN2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:12583068-12583089 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SKIV2L2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:55416036-55416059 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TMEM33 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:41954778-41954800 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ELAVL2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr9:23690279-23690301 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NUCKS1 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:205716333-205716355 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
EZR (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:158766109-158766132 (UNKNOWN)
AGO2 immunoprecipitation with monoclonal anti-AGO2 antibodies (C1.9E8.2). T1 RNase treatment.
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
OAS2 (hsa)
hsa-miR-302c-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:113011139-113011162 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0